News for Medigene AG (0QGJ.L)

PR NewswireBASEL, Switzerland, March 25, 2025 BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare com

**media[551809,551810]**

**media[544113]**

**media[531040]**

**media[486859]**

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

**media[460375]**

Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...

Medigene AG reports Q3 2024 revenues of €1.4M, reiterates guidance for 2024, and holds €9.5M in cash and equivalents.

Planegg/Martinsried, October 17, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...

Planegg/Martinsried, October 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...

Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...

Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the...

Presentation of the proposed board members to the Annual General Meeting on 13 May 2024 Jesper Høiland - born 1960, chairman Education:...

Europe's booming botanical drug market is expected to reach a whopping USD 1.1 billion by 2031, driven by high cancer rates and a surge in research on...

The growth of the market for Neoantigen cancer vaccines is primarily attributable to rapid technological advancements and improvements in the healthcare...